Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling

Biochemical Pharmacology

Volumn 68, Issue 1, 2004, Pages 41-50

  Ge, Rongrong ^a   Rajeev, Vaishali ^a   Subramanian, Gayathri ^a   Reiss, Kim A ^a   Liu, David ^b,c   Higgins, Linda ^b   Joly, Alison ^b,d   Dugar, Sundeep ^b   Chakravarty, Jit ^b   Henson, Margaret ^b   McEnroe, Glenn ^b   Schreiner, George ^b   Reiss, Michael ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b SCIOS INC   (United States)

^c FIBROGEN INC   (United States)

^d EXELIXIS INC   (United States)

Author keywords

dimethylsulfoxide; DMSO; FBS; fetal bovine serum; MAPK; mitogen activated protein kinase; SDS PAGE; T KI; T R kinase inhibitor; T R I; T R II; TGF ; TGF type I receptor; TGF type II receptor; transforming growth factor

Indexed keywords

ADENOSINE TRIPHOSPHATE; QUINAZOLINE DERIVATIVE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; BINDING SITE; BREAST EPITHELIUM; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DERIVATIZATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; IC 50; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; DNA-BINDING PROTEINS; DRUG INTERACTIONS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; MICE; PEPTIDES; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 2942536310     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.03.011     Document Type: Article

References (44)

1. Roberts A.B., Flanders K.C., Heine U.I., Jakowlew S., Kondaiah P., Kim S.J., et al. Transforming growth factor-beta: multifunctional regulator of differentiation and development. Philos Trans Royal Soc Lon B Biol Sci. 327(1239):1990;145-154
2. Massagué J. TGFβ signal transduction. Annu Rev Biochem. 67:1998;753-791
3. Hill C.S. The Smads. Int J Biochem Cell Biol. 31(11):1999;1249-1254
4. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21(14):2002;3749-3759
5. Reiss M. TGFβ and cancer. Microbes Infect. 1(15):1999;1327-1347
6. Fynan T.M., Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog. 4:1993;493-540
7. Branton M.H., Kopp J.B. TGF-beta and fibrosis. Microbes Infect. 1(15):1999;1349-1365
8. Sime P.J., O'Reilly K.M. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 99(3):2001;308-319
9. Chen W., Wahl S.M. Manipulation of TGF-beta to control autoimmune and chronic inflammatory diseases. Microbes Infect. 1(15):1999;1367-1380
10. Omer F.M., Kurtzhals J.A., Riley E.M. Maintaining the immunological balance in parasitic infections: a role for TGF-beta? Parasitol Today. 16(1):2000;18-23
11. Dumont N., Arteaga C.L. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 3(6):2003;531-536
12. Huse M., Muir T.W., Xu L., Chen Y.G., Kuriyan J., Massague J. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell. 8(3):2001;671-682
13. Yan W., Vellucci V.F., Reiss M. Smad protein expression and activation in transforming growth factor-beta refractory human squamous cell carcinoma cells. Oncol Res. 12(3):2000;157-167
14. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 71(6):1992;1003-1014
15. Eyers P.A., Craxton M., Morrice N., Cohen P., Goedert M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol. 5(6):1998;321-328
16. Cohen P., Goedert M. Engineering protein kinases with distinct nucleotide specificities and inhibitor sensitivities by mutation of a single amino acid. Chem Biol. 5(7):1998;R161-R164
17. Xie W., Kim D., Haffty B.G., Rimm D.L., Reiss M. Frequent alterations of Smad signaling in human head-&-neck squamous cell carcinomas - a tissue microarray analysis. Oncol Res. 14:2003;61-73
18. Yang Y.C., Piek E., Zavadil J., Liang D., Xie D., Heyer J., et al. Hierarchical model of gene regulation by transforming growth factor beta. Proc Natl Acad Sci USA. 100(18):2003;10269-10274
19. Reiss M., Dibble C.L. Reinitiation of DNA synthesis in quiescent mouse keratinocytes; regulation by polypeptide hormones. In Vitro. 24:1988;537-544
20. Miettinen P.J., Ebner R., Lopez A.R., Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. 127(6 Pt 2):1994;2021-2036
21. Piek E., Moustakas A., Kurisaki A., Heldin C.H., ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci. 112(Pt 24):1999;4557-6458
22. Arteaga C.L., Hurd S.D., Winnier A.R., Johnson M.D., Fendly B.M., Forbes J.T. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 92:1993;2569-2576
23. Isaka Y., Brees D.K., Ikegaya K., Kaneda Y., Imai E., Noble N.A., et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med. 2(4):1996;418-423
24. Bandyopadhyay A., Zhu Y., Cibull M.L., Bao L., Chen C., Sun L. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res. 59(19):1999;5041-5046
25. Isaka Y., Tsujie M., Ando Y., Nakamura H., Kaneda Y., Imai E., et al. Transforming growth factor-beta1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int. 58(5):2000;1885-1892
26. Bandyopadhyay A., Zhu Y., Malik S.N., Kreisberg J., Brattain M.G., Sprague E.A., et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene. 21(22):2002;3541-3551
27. McEarchern J.A., Kobie J.J., Mack V., Wu R.S., Meade-Tollin L., Arteaga C.L., et al. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer. 91(1):2001;76-82
28. Yang Y.A., Dukhanina O., Tang B., Mamura M., Letterio J., MacGregor J., et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest. 109(12):2002;1607-1615
29. Muraoka R.S., Dumont N., Ritter C.A., Dugger T.C., Brantley D.M., Chen J., et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 109(12):2002;1551-1559
30. Kobie J.J., Wu R.S., Kurt R.A., Lou S., Adelman M.K., Whitesell L.J., et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63(8):2003;1860-1864
31. Nakao A., Fujii M., Matsumura R., Kumano K., Saito Y., Miyazono K., et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest. 104(1):1999;5-11
32. Nakao A., Miike S., Hatano M., Okumura K., Tokuhisa T., Ra C., et al. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med. 192(2):2000;151-158
33. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 100(6):2002;1965-1971
34. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347(7):2002;472-480
35. Xie W., Mertens J.C., Reiss D.J., Rimm D.L., Camp R.L., Haffty B.G., et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome-a tissue microarray study. Cancer Res. 62:2002;497-505
36. Boyer A.S., Erickson C.P., Runyan R.B. Epithelial-mesenchymal transformation in the embryonic heart is mediated through distinct pertussis toxin-sensitive and TGFbeta signal transduction mechanisms. Dev Dyn. 214(1):1999;81-91
37. Brown C.B., Boyer A.S., Runyan R.B., Barnett J.V. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science. 283(5410):1999;2080-2082
38. Wakefield L.M., Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12(1):2002;22-29
39. Yakymovych I., Engstrom U., Grimsby S., Heldin C.H., Souchelnytskyi S. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase. Biochemistry. 41(36):2002;11000-11007
40. Callahan J.F., Burgess J.L., Fornwald J.A., Gaster L.M., Harling J.D., Harrington F.P., et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem. 45(5):2002;999-1001
41. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 62(1):2002;65-74
42. Laping N.J., Grygielko E., Mathur A., Butter S., Bomberger J., Tweed C., et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 62(1):2002;58-64
43. Sawyer J.S., Anderson B.D., Beight D.W., Campbell R.M., Jones M.L., Herron D.K., et al. Synthesis and activity of new aryl- and heteroaryl- substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem. 46(19):2003;3953-3956
44. DaCosta Byfield S., Major C., Laping N.J., Roberts A.B. SB-505124 is a selective inhibitor of transforming growth factor-{beta} type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 65(3):2004;744-752